首页> 外国专利> IMMUNOASSAY-BASED DETERMINATION OF IN-SOLUTION BINDING KINETICS

IMMUNOASSAY-BASED DETERMINATION OF IN-SOLUTION BINDING KINETICS

机译:基于免疫分析的溶液内结合动力学测定

摘要

FIELD: pharmaceuticals.;SUBSTANCE: invention relates to a method for determining the binding affinity of a drug to its target, comprising the following steps: determining the fraction of free drug or free target in a sample, comprising a drug, target and non-covalent drug-target-complexes in the drug concentration range at a constant target concentration, where the free drug fraction remains constant, by determining, based on the result of an immunoassay, the fraction of free drug in a drug-containing sample, target and drug-target-complexes, for at least two different drug ratios: the target in the sample and, if a certain fraction of the free drug is not comparable for all used ratios of the drug: the target, then the ratio of the drug: the target in the sample is reduced, and the sample is reanalyzed by the same immunoassay, or based on the result of the immunoassay, of the proportion of the free target in the sample, containing the drug and target-drug-complexes, for at least two different drug-target ratios: the target in the sample, and, if a certain fraction of the free target is not comparable for all used ratios of the drug: target, then the drug: target ratio in the sample is increased and the sample is reanalyzed by the same immunoassay, and the calculation based on the proportion of free drug or calculation based on the proportion of the free target, determined at the previous stage, the affinity of the binding of the drug to its target, where "comparable" means the relative difference (% of differences) of two specified values of less than 100 %, and "incomparable" means the relative difference (% difference) of two defined values greater than 100 % where % is difference, calculated according to the following formula % dif. = [(highest value) – (lowest value)] / (arithmetic mean), where to calculate the binding affinity (KD) apply the following equation: KD = (free drug share) * (target concentration [nM] / (1 – free drug fraction).;EFFECT: technical result of the invention lies in the fact that the determination of the affinity of the binding agent and its ligand in the samples can be carried out using very limited (small) number of measurements (samples), which reduces the complexity of the method and improves its accuracy.;12 cl, 6 ex, 11 dwg
机译:确定药物与其靶标的结合亲和力的方法,包括以下步骤:确定样品中游离药物或游离靶标的比例,包括药物,靶标和非靶标。药物浓度范围内的共价药物-靶标复合物,在恒定的靶标浓度下,其中游离药物分数保持恒定,方法是基于免疫测定的结果确定含药样品,靶标和药物-靶标复合物,对于至少两种不同的药物比率:样品中的靶标,以及如果一定比例的游离药物与药物:靶标的所有使用比率均不具有可比性,则药物的比率:减少样品中的靶标,然后通过相同的免疫测定法或基于免疫测定法的结果,对样品中游离靶标中含有药物和靶标-药物复合物的比例进行重新分析至少两天ifferent药物-靶标比率:样品中的靶标,并且,如果一定比例的游离靶标与药物:靶标的所有使用比率均不具有可比性,则样品中的药物:靶标比值将增加,样品为通过相同的免疫测定重新分析,并根据游离药物的比例进行计算或基于游离靶标的比例进行计算(在上一阶段确定),即药物与靶标结合的亲和力,其中“可比”是指小于100%的两个指定值的相对差异(差异百分比),“无可比”表示大于100%的两个定义值的相对差异(差异百分比),其中%是差异,根据下式%计算差异= [((最高值)–(最低值)] /(算术平均值),在哪里计算结合亲和力(K D ),应用以下公式:K D = (游离药物份额)*(目标浓度[nM] /(1-游离药物分数)。)效果:本发明的技术结果在于确定样品中结合剂及其配体的亲和力可以可以使用非常有限的(少量)测量值(样本)来执行,这降低了方法的复杂性并提高了方法的准确性。; 12 cl,6 ex,11 dwg

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号